Belumosudil
Evidence level: registry descriptions only; investigational; no results posted
A drug tested as the study intervention in two registered CLAD trials (ROCKaspire and CTOT-47); no results are posted for either.
As of . Primary source: ClinicalTrials.gov NCT06476132 (CTOT-47).
Summary
The registry entry for CTOT-47 (NCT06476132) describes belumosudil as an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD, and states that it is approved by the FDA to treat chronic graft-versus-host disease in adults and children aged 12 years and older. The ROCKaspire entry (NCT06082037) describes belumosudil compared with placebo in adults with progressive CLAD despite azithromycin. Neither registry entry posts results, and no published trial result was read, so no statement about efficacy or safety in CLAD is made. The status of belumosudil as a CLAD treatment is investigational. This record gives no dosing and no advice.
Details
- interventionType
- drug (investigational for CLAD)
Sources and links
Related
Linked from (derived)
Known gaps in this record
- published results: none read
- mechanism of action in CLAD: only the registry statement is quoted
- dosing: deliberately not recorded
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.